Vitamin D, C-reactive Protein and Insulin Resistance

NCT ID: NCT01019642

Last Updated: 2009-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2008-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized, double blind, placebo-controlled clinical trial of vitamin D supplementation (cholecalciferol, 4,000 IU/day for 6 months, in 104 postmenopausal women with type 2 diabetes mellitus.

The objective was to evaluate the effect of vitamin D supplementation on C-reactive protein (CRP) and insulin resistance in women with type 2 diabetes mellitus (T2DM).

The trial was conducted from March to October 2008 at the Hospital of the Mexican Social Security in Cuernavaca, Mexico.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Methods. Randomized, double blind, placebo-controlled clinical trial. We selected 104 postmenopausal women, ages 45 to 65, with uncomplicated T2DM and BMI ≥25. Women with history of kidney or liver disease, BMI\>40, autoimmune disease or cancer were not included in the study.

Participants were randomly assigned to receive either a capsule containing 4,000 IU of vitamin D3 (cholecalciferol, n=52) or placebo (n=52), once a day during 6 months.

Outcome variables were serum CRP, measured with a high-sensitivity assay (nephelometry), and HOMA-IR. Serum vitamin D (25-OH-D) was measured by HPLC. Outcome variables were measured at baseline, and 3 and 6 months thereafter. All participants received diet and physical activity counseling, and visited the clinic for medical check-up once a month.

Baseline Results. Mean age was 56.8 ± 5.1 y. Baseline BMI was 30.7 ± 3.9. Median CRP concentration was 5.0 mg/L (Interquartile range: 1.0, 8.5). HOMA index at baseline was 7.13 ± 3.8. Serum 25-OH-D concentration at baseline was 54.5 ± 15.7 nmol/L (\~22 ng/mL). Almost 94% of patients had baseline serum 25-OH-D levels \<80 nmol/L, and 25% were below 40 nmol/L. No one had levels \<20 nmol/L. There were no statistical differences on important variables by treatment group at the onset of study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Low-intensity Chronic Inflammation Insulin Resistance

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

vitamin D diabetes C-reactive protein insulin resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin D

Cholecalciferol, 4,000 IU/d for 6 months

Group Type EXPERIMENTAL

cholecalciferol

Intervention Type DRUG

4,000 IU per day during 6 months. Capsule form.

Placebo

placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

no active principles given.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cholecalciferol

4,000 IU per day during 6 months. Capsule form.

Intervention Type DRUG

placebo

no active principles given.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes mellitus w/ \< 10 yrs of diagnosis
* Postmenopausal
* Overweight or obesity (BMI \>=25)
* Treated with metformin

Exclusion Criteria

* BMI \>=40
* Liver or kidney disease
* Other important chronic disease: i.e. cancer, autoimmune.
* Receiving insulin
Minimum Eligible Age

45 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto Mexicano del Seguro Social

OTHER_GOV

Sponsor Role collaborator

Ellison Medical / International Nutrition Foundation

UNKNOWN

Sponsor Role collaborator

Tufts University

OTHER

Sponsor Role collaborator

Instituto Nacional de Salud Publica, Mexico

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Instituto Nacional de Salud Publica

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mario E Flores, MD, MSc

Role: PRINCIPAL_INVESTIGATOR

Instituto Nacional de Salud Publica, Mexico

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Instituto Mexicano del Seguro Social

Cuernavaca, Morelos, Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Mexico

References

Explore related publications, articles, or registry entries linked to this study.

Flores M. A role of vitamin D in low-intensity chronic inflammation and insulin resistance in type 2 diabetes mellitus? Nutr Res Rev. 2005 Dec;18(2):175-82. doi: 10.1079/NRR2005104.

Reference Type BACKGROUND
PMID: 19079903 (View on PubMed)

Munoz-Aguirre P, Flores M, Macias N, Quezada AD, Denova-Gutierrez E, Salmeron J. The effect of vitamin D supplementation on serum lipids in postmenopausal women with diabetes: A randomized controlled trial. Clin Nutr. 2015 Oct;34(5):799-804. doi: 10.1016/j.clnu.2014.10.002. Epub 2014 Oct 13.

Reference Type DERIVED
PMID: 25453396 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

120-6371

Identifier Type: -

Identifier Source: org_study_id